Published in J Nat Sci on May 20, 2016
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Recent progress in tumor pH targeting nanotechnology. J Control Release (2008) 1.94
Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res (1998) 1.68
Colon cancer. Crit Rev Oncol Hematol (2010) 1.62
5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules (2008) 1.48
Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res (2000) 1.48
Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res (1995) 1.08
Cholesteryl hemisuccinate exhibits pH sensitive polymorphic phase behavior. Biochim Biophys Acta (2000) 1.03
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol (2003) 1.00
Nanoparticles for combination drug therapy. ACS Nano (2013) 0.99
Investigation of single-drug-encapsulating liposomes using the nano-impact method. Angew Chem Int Ed Engl (2014) 0.95
The β6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett (2012) 0.93
Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. J Control Release (2014) 0.91
High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res (1999) 0.90
Predicting the outcome of chemotherapy for colorectal cancer. Curr Opin Pharmacol (2006) 0.90
Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior. Biomaterials (2014) 0.90
Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr Med Chem (2009) 0.87
pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS One (2013) 0.86
Evaluation of polymeric nanoparticle formulations by effective imaging and quantitation of cellular uptake for controlled delivery of doxorubicin. Small (2014) 0.81
The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles. Int J Pharm (2014) 0.80
Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs. Eur J Med Chem (2011) 0.78
Cytotoxicity of 5-fluorouracil-loaded pH-sensitive liposomal nanoparticles in colorectal cancer cell lines. Integr Cancer Sci Ther (2015) 0.78
Polymeric nanoparticles for oral delivery of 5-fluorouracil: Formulation optimization, cytotoxicity assay and pre-clinical pharmacokinetics study. Eur J Pharm Sci (2016) 0.77